Dana Cernea

2.8k total citations · 1 hit paper
16 papers, 2.0k citations indexed

About

Dana Cernea is a scholar working on Genetics, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Dana Cernea has authored 16 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Genetics, 6 papers in Oncology and 6 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Dana Cernea's work include Glioma Diagnosis and Treatment (11 papers), Radiomics and Machine Learning in Medical Imaging (4 papers) and Brain Metastases and Treatment (4 papers). Dana Cernea is often cited by papers focused on Glioma Diagnosis and Treatment (11 papers), Radiomics and Machine Learning in Medical Imaging (4 papers) and Brain Metastases and Treatment (4 papers). Dana Cernea collaborates with scholars based in Romania, France and United Kingdom. Dana Cernea's co-authors include Petr Kavan, Olivier Chinot, Khê Hoang‐Xuan, Wolfgang Wick, Ryo Nishikawa, Timothy F. Cloughesy, Magalie Hilton, Alain Carpentier, Roger Henriksson and Alba A. Brandes and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Annals of Oncology.

In The Last Decade

Dana Cernea

13 papers receiving 2.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Bevacizumab plus Radiotherapy–Temozolomide for Newly Diagnosed Glioblastoma

2014 1.8k citations Olivier Chinot, Wolfgang Wick et al. New England Journal of Medicine profile →

Peers

Countries citing papers authored by Dana Cernea

Since Specialization

Citations

This map shows the geographic impact of Dana Cernea's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dana Cernea with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dana Cernea more than expected).

Fields of papers citing papers by Dana Cernea

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dana Cernea. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dana Cernea. The network helps show where Dana Cernea may publish in the future.

Co-authorship network of co-authors of Dana Cernea

This figure shows the co-authorship network connecting the top 25 collaborators of Dana Cernea. A scholar is included among the top collaborators of Dana Cernea based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dana Cernea. Dana Cernea is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

#	Work	Indexed citations
1	Deep-learning magnetic resonance imaging-based automatic segmentation for organs-at-risk in the brain: Accuracy and impact on dose distribution 2023 ·Physics and Imaging in Radiation Oncology ·(unknown), Daniel‐Corneliu Leucuta, (unknown), E. Clementel, (unknown), (unknown), Sarah M. Kelly, (unknown), Dana Cernea, Patriciu Achimaș-Cădariu	12
2	Tomotherapy for cranio-spinal irradiation 2022 ·Clinical and Translational Radiation Oncology ·(unknown), Sarah M. Kelly, E. Clementel, Dana Cernea	3
3	ACTR-78. TAMIGA: A PHASE II STUDY EVALUATING THE EFFICACY AND SAFETY OF CONTINUOUS BEVACIZUMAB THROUGH MULTIPLE LINES OF TREATMENT FOR GLIOBLASTOMA 2017 ·Neuro-Oncology ·Alba A. Brandes, (unknown), Frank Saran, Alain Carpentier, Anna K. Nowak, Warren Mason, François Dubois, Gaetano Finocchiaro, George Fountzilas, Vittorina Zagonel, Dana Cernea, Olivier Chinot, Martina Makrutzki, Chiedzo Mpofu, (unknown), Josef Pichler	1
4	Randomized Phase II Study of Duligotuzumab (MEHD7945A) vs. Cetuximab in Squamous Cell Carcinoma of the Head and Neck (MEHGAN Study) 2016 ·Frontiers in Oncology ·Jérôme Fayette, Lori J. Wirth, Cristina Oprean, Anghel Adrian Udrea, Antonio Jimeno, Danny Rischin, Christopher M. Nutting, Paul M. Harari, Tibor Csőszi, Dana Cernea, Paul E. O’Brien, William D. Hanley, Amy V. Kapp, Maria Anderson, Elicia Penuel, Bruce McCall, Andrea Pirzkall, Jan B. Vermorken	84
5	ACTR-19. BASELINE PLASMA MATRIX METALLOPROTEINASE 9 (MMP9) PREDICTS OVERALL SURVIVAL (OS) BENEFIT FROM BEVACIZUMAB INDEPENDENTLY OF MOLECULAR SUBTYPES IN NEWLY DIAGNOSED GLIOBLASTOMA: RETROSPECTIVE ANALYSIS OF AVAglio 2016 ·Neuro-Oncology ·Olivier Chinot, Josep Garcia, Sylvie Romain, Cédric Révil, Timothy F. Cloughesy, Warren Mason, Ryo Nishikawa, Roger Henriksson, Frank Saran, Alain Carpentier, Khê Hoang‐Xuan, Petr Kavan, Dana Cernea, Alba A. Brandes, Yannick Kerloëguen, Christoph Mancao, L’Houcine Ouafik, Lauren E. Abrey, Wolfgang Wick, Émeline Tabouret	0
6	Sensitizer drugs for the treatment of temozolomide-resistant glioblastoma. 2016 ·PubMed ·(unknown), (unknown), Olga Şoriţău, Ciprian Tomuleasa, (unknown), Oana Zănoagă, Dana Cernea, Cornelia Braicu, Ioana Berindan‐Neagoe, Ioan Ştefan Florian	12
7	Baseline plasma matrix metalloproteinase 9 (MMP9) to predict overall survival (OS) benefit from bevacizumab (BEV) in newly diagnosed glioblastoma (GBM): Retrospective analysis of AVAglio. 2016 ·Journal of Clinical Oncology ·Olivier Chinot, Josep Garcia, Sylvie Romain, Cédric Révil, Timothy F. Cloughesy, Warren Mason, Ryo Nishikawa, Roger Henriksson, Frank Saran, Alain Carpentier, Khê Hoang‐Xuan, Petr Kavan, Dana Cernea, Alba A. Brandes, Yannick Kerloëguen, Christoph Mancao, L’Houcine Ouafik, Lauren E. Abrey, Wolfgang Wick, Émeline Tabouret	2
8	Bevacizumab plus Radiotherapy–Temozolomide for Newly Diagnosed Glioblastoma breakdown → 2014 ·New England Journal of Medicine ·Olivier Chinot, Wolfgang Wick, Warren Mason, Roger Henriksson, Frank Saran, Ryo Nishikawa, Alain Carpentier, Khê Hoang‐Xuan, Petr Kavan, Dana Cernea, Alba A. Brandes, Magalie Hilton, Lauren E. Abrey, Timothy F. Cloughesy	1825
9	P13.05 * SECOND RADIOTHERAPY TREATMENT IN RECURRENT BRAIN TUMORS 2014 ·Neuro-Oncology ·Dana Cernea, (unknown), (unknown), (unknown), Stefan Florian, (unknown)	0
10	Randomized Phase Ii Study of Mehd7945A (Mehd) Vs Cetuximab (Cet) in >= 2Nd-Line Recurrent/Metastatic Squamous Cell Carcinoma of the Head & Neck (Rmscchn) Progressive On/After Platinum-Based Chemotherapy (Ptct) 2014 ·Annals of Oncology ·Jérôme Fayette, Lori J. Wirth, Cristina Oprean, Ricardo Hitt, Anghel Adrian Udrea, Antonio Jimeno, Danny Rischin, Chris Nutting, Paul M. Harari, (unknown), Dana Cernea, (unknown), Amy V. Kapp, (unknown), Elicia Penuel, (unknown), Andrea Pirzkall, Jan B. Vermorken	15
11	P17.16 * PRIMARY CENTRAL NERVOUS SYSTEM TUMORS IN YOUNG ADULTS: PATHOLOGY AND TREATMENT RESULTS 2014 ·Neuro-Oncology ·Dana Cernea, (unknown), (unknown), (unknown), Stefan Florian, (unknown)	0
12	FINAL EFFICACY AND SAFETY RESULTS FROM AVAglio, A PHASE III TRIAL OF BEVACIZUMAB (BEV) PLUS TEMOZOLOMIDE (TMZ) ANDRADIOTHERAPY (RT) IN NEWLY DIAGNOSED GLIOBLASTOMA 2013 ·Neuro-Oncology ·Olivier Chinot, Wolfgang Wick, Warren Mason, Roger Henriksson, Frank Saran, Ryo Nishikawa, Alain Carpentier, Khê Hoang‐Xuan, Petr Kavan, Dana Cernea, Alba A. Brandes, Magalie Hilton, Yannick Kerloëguen, (unknown), (unknown)	3
13	Progression-free survival (PFS) and health-related quality of life (HRQoL) in AVAglio, a phase III study of bevacizumab (Bv), temozolomide (T), and radiotherapy (RT) in newly diagnosed glioblastoma (GBM). 2013 ·Journal of Clinical Oncology ·Roger Henriksson, Andrew Bottomley, Warren Mason, Frank Saran, Wolfgang Wick, Ryo Nishikawa, Timothy F. Cloughesy, Alain Carpentier, Khê Hoang‐Xuan, Petr Kavan, Dana Cernea, Alba A. Brandes, Magalie Hilton, (unknown), Arliene Ravelo, Olivier Chinot	24
14	Arsenic trioxide sensitizes cancer stem cells to chemoradiotherapy. A new approach in the treatment of inoperable glioblastoma multiforme. 2011 ·PubMed ·Ciprian Tomuleasa, (unknown), Gabriel Kacsó, Eva Fischer‐Fodor, (unknown), (unknown), (unknown), (unknown), Dana Cernea, (unknown), Alexandra Iulia Irimie, Ioan Ştefan Florian	15
15	Functional and molecular characterization of glioblastoma multiforme-derived cancer stem cells. 2010 ·PubMed ·Ciprian Tomuleasa, (unknown), (unknown), (unknown), Sergiu Șușman, (unknown), (unknown), Dana Cernea, Gabriel Kacsó, Alexandru Irimie, Ioan Ştefan Florian	15
16	Concurrent chemoradiotherapy with vinorelbine and a platinum compound followed by consolidation chemotherapy for unresectable stage III non-small cell lung cancer: preliminary results of a phase II study. 2007 ·PubMed ·(unknown), Tudor–Eliade Ciuleanu, Dana Cernea, (unknown), Valéria Gaál, C. Cebotaru, (unknown), (unknown), N. Ghilezan	5

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact